Ongoing Clinical Trials for Amnestic Disorder
There is currently 1 ongoing clinical trial investigating treatments for amnestic disorder, specifically focusing on amnestic mild cognitive impairment and early Alzheimer’s Disease. This trial is exploring the potential of senolytic therapy using a combination of two medications to slow disease progression.
Clinical trial locations
Study on the Safety of Dasatinib and Quercetin for Patients with Mild Cognitive Impairment or Early Alzheimer’s Disease
This clinical trial is investigating a novel treatment approach for individuals experiencing early memory problems. The study focuses on people diagnosed with amnestic mild cognitive impairment (aMCI), which involves noticeable memory problems that are greater than expected for someone’s age, or early-stage Alzheimer’s Disease. The treatment being tested combines two medications: Dasatinib and Quercetin.
Main inclusion criteria:
- Participants must be 60 years or older
- Must have a diagnosis of amnestic mild cognitive impairment or early-stage Alzheimer’s Disease
- Must have elevated tau protein levels in cerebrospinal fluid, which is a marker associated with brain changes
- Must have a study partner who has regular contact (about 10 hours per week) and can provide information about the participant’s thinking and daily abilities
- Must speak Spanish fluently and have at least six years of formal education
- Must be fully vaccinated against COVID-19 with at least two doses, received at least 30 days before starting the study
- Can continue taking approved Alzheimer’s medications such as donepezil, rivastigmine, or galantamine if the dose has been stable for at least three months
- Must have normal blood cell counts, liver and kidney function, cholesterol below 240 mg/dl, and HbA1c at 7% or less
Main exclusion criteria:
- Patients with other significant medical conditions that could interfere with the study
- Those currently participating in another clinical trial
- Patients who have had recent major surgery or are planning surgery during the study
- History of severe allergic reactions to the study medications
- Women who are pregnant or breastfeeding
- History of drug or alcohol abuse within the past year
- History of cancer within the past five years (with some exceptions for certain skin cancers)
- Patients with severe liver or kidney disease
- Unstable or serious medical conditions that could affect safety or study results
Focus and goal of the trial:
The primary goal of this study is to evaluate the safety and feasibility of using a combination of Dasatinib and Quercetin over a 12-week treatment period. This approach is known as senolytic therapy, which means it targets and removes certain aging cells in the body that no longer function properly. These damaged cells may contribute to the progression of Alzheimer’s Disease and memory problems.
The study will monitor participants’ health and any side effects that may occur during treatment. Researchers will also look at changes in specific markers in the blood that are associated with aging cells, as well as any changes in memory and cognitive function over time. Participants will undergo regular check-ups and blood tests throughout the study. The entire trial lasts for 48 weeks, including follow-up visits after the initial 12-week treatment period.
Investigational drugs:
Dasatinib is a medication typically used to treat certain types of cancer, but researchers are exploring whether it can help remove damaged cells in the brain that might contribute to Alzheimer’s Disease. By clearing out these harmful cells, it might slow down disease progression.
Quercetin is a natural substance found in many fruits and vegetables. In this trial, it is being used alongside Dasatinib to potentially help improve the condition of people with memory impairment and Alzheimer’s Disease. Quercetin is thought to have properties that might help clear out harmful cells in the brain.
Both medications are taken orally in the form of film-coated tablets. Together, they work as senolytic agents to target aging cells that may be contributing to cognitive decline.
Summary
Currently, there is one clinical trial available for patients with amnestic disorder, specifically those with amnestic mild cognitive impairment or early Alzheimer’s Disease. This trial is being conducted in Spain and represents an innovative approach to treating memory disorders by targeting aging cells in the brain. The study focuses on evaluating the safety and feasibility of combining Dasatinib and Quercetin as a potential therapy to slow disease progression. This represents a Phase II trial exploring senolytic therapy, a relatively new area of research in the field of neurodegenerative diseases. Patients interested in this trial must meet specific criteria, including age requirements, disease stage, and biomarker evidence of brain changes.